IR Information
| No. | Title | Writer | Date |
|---|---|---|---|
| 12 | 44th Annual J.P. Morgan Healthcare Conference Presentation | 알테오젠 | 2026-01-16 |
| 11 | Analyst report: Hana Securities Inc.(25.11.20.) | Alteogen | 2025-11-20 |
| 10 | Analyst report: DAOL Investment & Securities(25.11.12.) | Alteogen | 2025-11-12 |
| 9 | Analyst report : Kyobo Securities(25.10.15.) | Alteogen | 2025-10-15 |
| 8 | Analyst report: CLSA (2025.09.22.) | Alteogen | 2025-09-22 |
| 7 | Analyst report: Hana Securities Inc.(25.09.22.) | Alteogen | 2025-09-22 |
| 6 | Analyst report: Macquarie (2025.09.22.) | Alteogen | 2025-09-22 |
| 5 | Analyst report: Shinhan Securities(25.09.22.) | Alteogen | 2025-09-22 |
| 4 | Business Update: Daiichi Sankyo Initiates Phase 1 Clinical Trial for the SC Formulation of Enhertu Using ALT-B4 | Alteogen | 2025-06-13 |
| 3 | Business Update: US patent Regstration Schedule for ALT-B4 | Alteogen | 2025-04-25 |
Contact Investor Relations
+82-42-384-8777
ir@alteogen.com